La vendita allo scoperto per Janux Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Janux Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Janux Therapeutics (NASDAQ:JANX) Azioni, Report sulle vendite allo scoperto

Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Janux Therapeutics Inc

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 60 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $77.80 million which beat the analyst consensus estimate of $75.83 million by 2.60 percent. This is a 4.59 percent decrease over sales of $81.54 million the same period last year.

Earnings

Earnings Beats

News

Eventbrite Q3 EPS $(0.04) Beats $(0.13) Estimate, Sales $77.80M Beat $75.83M Estimate

Arlo Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) is looking for Q4 Adj EPS of $0.07-0.13 vs $0.11 analyst estimate. sees sales of $116.000 million-126.000 million vs $138.94 million estimate.

Guidance

ARLO

Arlo Technologies Sees Q4 Adj EPS $0.07-0.13 vs $0.11 Est; Sees Sales $116.000M-126.000M vs $138.94M Est

Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics from the <a href="https://www.benzinga.com/pressreleases/24/11/n41823730/lucid-announces-third-quarter-2024-financial-results">electric vehicle company&#8217;s quarter</a>.
Q3 Earnings: Lucid reported third-quarter revenue of $200.04 million, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $197.97 million, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The EV company reported an adjusted quarterly loss of 28 cents per share, beating analyst estimates for a loss of 30 cents per share.
Lucid said it produced 1,805 vehicles in the third quarter and delivered 2,781.&nbsp;The company ended the quarter with approximately $5.16 billion in total liquidity.
&#8220;Our momentum continues with our third consecutive quarter of record deliveries,&#8221; said&nbsp;Peter Rawlinson, CEO and CTO of Lucid.
 &#8220;Additionally, today we are delighted to open the order book for the much-anticipated Lucid Gravity SUV, a landmark product, which remains on track for start of production this year. Furthermore, our recent capital raise of approximately&nbsp;$1.75&nbsp;billion serves to further secure the future of the company by extending its financial runway well into 2026.&#8221;
Related Link: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Outlook: Lucid said it remains on track to produce approximately 9,000 vehicles in 2024.
The company announced Thursday morning that its&nbsp;Gravity Grand Touring&nbsp;SUV became available to order. Lucid expects production to start at the end of the year.
&#8220;We continue to see improvements to gross margin performance as our cost reduction efforts are gaining momentum,&#8221; said&nbsp;Gagan Dhingra, interim CFO and principal accounting officer at Lucid.&nbsp;
Management will hold a conference call to further discuss the company&#8217;s quarterly results at 5:30 p.m. ET.
LCID Price Action: <a href="https://www.benzinga.com/quote/LCID" target="_blank" rel="noreferrer noopener">Lucid shares</a> were up 8.09% in after-hours, trading at $ 2.39 at the time of publication, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Lucid.

After-Hours Center

Movers

LCID

Lucid Q3 Earnings: Revenue Beat, EPS Beat, On Track To Produce 9K Vehicles In 2024

Management

COLL

Collegium Names Vikram Karnani As CEO, Effective Nov. 12; Former Horizon Therapeutics Executive To Lead Growth And Expansion

FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $140.209 million which missed the analyst consensus estimate of $143.138 million by 2.05 percent. This is a 1.51 percent decrease over sales of $142.364 million the same period last year.

Earnings Misses

FIGS

FIGS Q3 2024 Adj. EPS $(0.01), Inline, Sales $140.209M Miss $143.138M Estimate

Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) .

PBPB

Potbelly FY2024 Guidance: Same Store Sales -1.2% to -0.5%, Adj. EBITDA $29.5M-$30.5M.

Gross margin in the range of 70% to 71%, up from previous guidance range of 68% to 70%.
&nbsp;
&nbsp;

RXST

RxSight Now Sees FY24 Revenue At The Top Of Previously Provided Guidance Range Of $139M - $140M, Est $139.642M

Dividends

EOG Resources Raises Quarterly Dividend From $0.91 To $0.975

Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.33) by 33.33 percent. This is a 21.43 percent increase over losses of $(0.28) per share from the same period last year.

RZLT

Rezolute Q1 EPS $(0.22) Beats $(0.33) Estimate

WIIM

JFBR

Jeffs' Brands shares are trading higher after the company announced it entered into a non-binding letter of intent for the sale of a subsidiary valued at $13.5 million.

Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.31) by 25.81 percent.

DSGN

Design Therapeutics Q3 2024 GAAP EPS $(0.23) Beats $(0.31) Estimate

Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $70.84 million which missed the analyst consensus estimate of $71.74 million by 1.26 percent. This is a 13.01 percent increase over sales of $62.68 million the same period last year.

CTLP

Cantaloupe Q1 EPS $0.04, Inline, Sales $70.84M Miss $71.74M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fidentiv.com&amp;esheet=54148677&amp;newsitemid=20241107448252&amp;lan=en-US&amp;anchor=Identiv%2C+Inc&amp;index=1&amp;md5=7038f21113fe10c77c0bb35b935bf53b">Identiv, Inc</a><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fidentiv.com&amp;esheet=54148677&amp;newsitemid=20241107448252&amp;lan=en-US&amp;anchor=.&amp;index=2&amp;md5=99b6eaee914a3599ca5133f57d2023b0">.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>), a global leader in RFID-enabled Internet of Things (IoT) solutions, today announced that its Board of Directors has authorized a stock repurchase program for up to $10 million of its common stock. The Company also announced its Board of Directors intends to propose changes to the Company's corporate governance policies in advance of the 2025 annual meeting of stockholders.

Buybacks

INVE

Identiv Announces $10M Stock Repurchase Program

Potbelly 4Q 24 Guidance: Same Store Sales -2.5% to -0.5%, Adj. EBITDA $7M-$8M.

PACB

Pacific Biosciences Says On The Path To Return To Growth In 2025 And Beyond

Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.39 by 30.77 percent. The company reported quarterly sales of $86.101 million which missed the analyst consensus estimate of $111.128 million by 22.52 percent. This is a 15.09 percent decrease over sales of $101.397 million the same period last year.

ADEA

Adeia Q3 2024 Adj. EPS $0.27 Misses $0.39 Estimate, Sales $86.101M Miss $111.128M Estimate

Block Sees FY24 Adj. EBITDA $2.90B

SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $888.72 thousand which missed the analyst consensus estimate of $1.10 million by 19.21 percent. This is a 39.38 percent decrease over sales of $1.47 million the same period last year.

SSSS

SuRo Capital Q3 EPS $(0.14) Beats $(0.15) Estimate, Sales $888.72K Miss $1.10M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ringcentral.com%2F&amp;esheet=54149025&amp;newsitemid=20241107126443&amp;lan=en-US&amp;anchor=RingCentral%2C+Inc.+%28NYSE%3A+RNG%29&amp;index=1&amp;md5=c2845406a58e8205490c85feb96a44fc">RingCentral, Inc. (NYSE:</a><a href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>), a global leader in AI-powered trusted business communications for companies of all sizes, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.verint.com%2F&amp;esheet=54149025&amp;newsitemid=20241107126443&amp;lan=en-US&amp;anchor=Verint%26%23174%3B+%28NASDAQ%3A+VRNT%29&amp;index=2&amp;md5=ff2052d631e7be32c2f061531c2594a7">Verint&#xAE; (NASDAQ:</a><a href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>), a leader in CX automation, today announced a strategic partnership to provide <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ringcentral.com%2Fringcx.html&amp;esheet=54149025&amp;newsitemid=20241107126443&amp;lan=en-US&amp;anchor=RingCX&amp;index=3&amp;md5=9b55f66ae5a500a88ea806afa45513bd">RingCX</a>&#x2122; customers access to best-in-class workforce engagement management (WEM) and CX automation. Through this partnership, RingCX customers will have more choice and be able to leverage Verint's leading WEM and CX automation solutions, which complement RingCentral's native AI capabilities, to enhance employee productivity and improve customer experiences, ultimately driving competitive advantage and operational efficiency.

VRNT

RingCentral And Verint Announce Strategic Partnership To Bring AI-Powered Workforce Engagement Management And CX Automation To RingCX Customers

Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. The company reported quarterly sales of $20.16 million which missed the analyst consensus estimate of $20.40 million by 1.18 percent. This is a 0.74 percent increase over sales of $20.01 million the same period last year.

SGHT

Sight Sciences Q3 2024 GAAP EPS $(0.22) Beats $(0.23) Estimate, Sales $20.16M Miss $20.40M Estimate

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report), Lyell Immuno...

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Lyell Immunopharma (LYEL) and Janux Therapeutics Inc (JANX)

Janux Therapeutics: Buoyed By Buyout Speculation

Janux initiated at Stifel with Buy on upcoming data update

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on October 24. Soumit Roy has given his Buy ...

Promising Outlook for Janux Therapeutics Ahead of Key Phase 1 Data Release

TD Cowen analyst Marc Frahm has maintained their bullish stance on JANX stock, giving a Buy rating on October 31. Marc Frahm's rating is based on p...

Promising Phase I Trial Results and Tolerability Boost Buy Rating for Janux Therapeutics' JANX007 in mCRPC Treatment

Janux Therapeutics GAAP EPS of -$0.51 misses by $0.13, revenue of $0.44M misses by $1.23M

In a report released today, Justin Zelin from BTIG maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report), with a price target ...

Janux Therapeutics Inc (JANX) Receives a Buy from BTIG

Scotiabank analyst George Farmer maintained a Hold rating on Janux Therapeutics Inc (JANX – Research Report) today and set a price target of $42.00...

Comments

Janux Therapeutics

Vendite allo scoperto

Janux Therapeutics (NASDAQ:JANX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO